497 related articles for article (PubMed ID: 29797644)
21. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
[TBL] [Abstract][Full Text] [Related]
22. A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease.
Rampersaud E; Kang G; Palmer LE; Rashkin SR; Wang S; Bi W; Alberts NM; Anghelescu D; Barton M; Birch K; Boulos N; Brandow AM; Brooke RJ; Chang TC; Chen W; Cheng Y; Ding J; Easton J; Hodges JR; Kanne CK; Levy S; Mulder H; Patel AP; Puri L; Rosencrance C; Rusch M; Sapkota Y; Sioson E; Sharma A; Tang X; Thrasher A; Wang W; Yao Y; Yasui Y; Yergeau D; Hankins JS; Sheehan VA; Downing JR; Estepp JH; Zhang J; DeBaun M; Wu G; Weiss MJ
Blood Adv; 2021 Jul; 5(14):2839-2851. PubMed ID: 34283174
[TBL] [Abstract][Full Text] [Related]
23. Sickle cell disease in western Sudan: genetic epidemiology and predictors of knowledge attitude and practices.
Daak AA; Elsamani E; Ali EH; Mohamed FA; Abdel-Rahman ME; Elderdery AY; Talbot O; Kraft P; Ghebremeskel K; Elbashir MI; Fawzi W
Trop Med Int Health; 2016 May; 21(5):642-53. PubMed ID: 27028397
[TBL] [Abstract][Full Text] [Related]
24. Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.
Colombatti R; Palazzi G; Masera N; Notarangelo LD; Bonetti E; Samperi P; Barone A; Perrotta S; Facchini E; Miano M; Del Vecchio GC; Guerzoni ME; Corti P; Menzato F; Cesaro S; Casale M; Rigano P; Forni GL; Russo G; Sainati L;
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28868627
[TBL] [Abstract][Full Text] [Related]
25. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
Tantawy AA; Adly AA; Ismail EA; Darwish YW; Ali Zedan M
Blood Cells Mol Dis; 2014 Dec; 53(4):189-93. PubMed ID: 25065856
[TBL] [Abstract][Full Text] [Related]
26. East Mediterranean region sickle cell disease mortality trial: retrospective multicenter cohort analysis of 735 patients.
Karacaoglu PK; Asma S; Korur A; Solmaz S; Buyukkurt NT; Gereklioglu C; Kasar M; Ozbalcı D; Unal S; Kaya H; Gurkan E; Yeral M; Sariturk Ç; Boga C; Ozdogu H
Ann Hematol; 2016 May; 95(6):993-1000. PubMed ID: 27068408
[TBL] [Abstract][Full Text] [Related]
27. Clinical Features of β-Thalassemia and Sickle Cell Disease.
McGann PT; Nero AC; Ware RE
Adv Exp Med Biol; 2017; 1013():1-26. PubMed ID: 29127675
[TBL] [Abstract][Full Text] [Related]
28. Serum angiogenin level in sickle cell disease and beta thalassemia patients.
Matter RM; Abdelmaksoud AA; Shams MA; Bebawy EK
Pediatr Hematol Oncol; 2014 Feb; 31(1):50-6. PubMed ID: 24483841
[TBL] [Abstract][Full Text] [Related]
29. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
[TBL] [Abstract][Full Text] [Related]
30. [Potential alternatives to erythrocyte transfusion in hemoglobinopathies: hydroxyurea (HU), erythropoietin (EPO), butyrate derivatives, blood substitutes].
Bachir D; Galacteros F
Transfus Clin Biol; 1994; 1(1):35-9. PubMed ID: 8186851
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London.
Telfer P; Coen P; Chakravorty S; Wilkey O; Evans J; Newell H; Smalling B; Amos R; Stephens A; Rogers D; Kirkham F
Haematologica; 2007 Jul; 92(7):905-12. PubMed ID: 17606440
[TBL] [Abstract][Full Text] [Related]
32. Assessing barriers and facilitators to transition in sickle cell disease care prior to implementation of a formalized program.
Sheppard S; Hellemann G; Lebensburger J; Kanter J
Pediatr Blood Cancer; 2023 Apr; 70(4):e30160. PubMed ID: 36617736
[TBL] [Abstract][Full Text] [Related]
33. Agreement between youth and caregiver report of pain and functioning in pediatric sickle cell disease: PedsQL sickle cell disease module.
Alberts NM; Gilbert A; Kang G; Okhomina VI; Flynn JS; Hodges J; Hankins JS; Klosky JL
Pain; 2024 Mar; 165(3):715-722. PubMed ID: 37878652
[TBL] [Abstract][Full Text] [Related]
34. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
Kassim AA; DeBaun MR
Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871
[TBL] [Abstract][Full Text] [Related]
35. Hydroxyurea can be used in children with sickle cell disease and cerebral vasculopathy for the prevention of chronic complications? A meta-analysis.
Núñez RM; Figueroa CAP; García-Perdomo HA
J Child Health Care; 2020 Mar; 24(1):64-77. PubMed ID: 30606035
[TBL] [Abstract][Full Text] [Related]
36. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study.
Bhakta N; Liu Q; Yeo F; Baassiri M; Ehrhardt MJ; Srivastava DK; Metzger ML; Krasin MJ; Ness KK; Hudson MM; Yasui Y; Robison LL
Lancet Oncol; 2016 Sep; 17(9):1325-34. PubMed ID: 27470081
[TBL] [Abstract][Full Text] [Related]
37. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years.
Chaturvedi S; DeBaun MR
Am J Hematol; 2016 Jan; 91(1):5-14. PubMed ID: 26547630
[TBL] [Abstract][Full Text] [Related]
38. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
Luchtman-Jones L; Pressel S; Hilliard L; Brown RC; Smith MG; Thompson AA; Lee MT; Rothman J; Rogers ZR; Owen W; Imran H; Thornburg C; Kwiatkowski JL; Aygun B; Nelson S; Roberts C; Gauger C; Piccone C; Kalfa T; Alvarez O; Hassell K; Davis BR; Ware RE
Am J Hematol; 2016 Feb; 91(2):238-42. PubMed ID: 26615793
[TBL] [Abstract][Full Text] [Related]
39. Clinical and genetic ancestry profile of a large multi-centre sickle cell disease cohort in Brazil.
Carneiro-Proietti ABF; Kelly S; Miranda Teixeira C; Sabino EC; Alencar CS; Capuani L; Salomon Silva TP; Araujo A; Loureiro P; Máximo C; Lobo C; Flor-Park MV; Rodrigues DOW; Mota RA; Gonçalez TT; Hoppe C; Ferreira JE; Ozahata M; Page GP; Guo Y; Preiss LR; Brambilla D; Busch MP; Custer B;
Br J Haematol; 2018 Sep; 182(6):895-908. PubMed ID: 30027669
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers of clinical severity in treated and untreated sickle cell disease: a comparison by genotypes of a single center cohort and African Americans in the NHANES study.
Njoku F; Zhang X; Shah BN; Machado RF; Han J; Saraf SL; Gordeuk VR
Br J Haematol; 2021 Aug; 194(4):767-778. PubMed ID: 34268729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
